Literature DB >> 12883226

An automated HPLC method to determine intracellular vincristine concentrations in mononuclear cells of children with acute lymphoblastic leukemia.

Ellis Groninger1, Pauline Koopmans, Willem Kamps, Siebold de Graaf, Donald Uges.   

Abstract

A method to determine intracellular vincristine concentrations in vivo in leukemic cells of patients is useful to investigate mechanisms of vincristine resistance. We developed a high-performance liquid chromatographic (HPLC) method to measure vincristine concentrations in human mononuclear cells (MNC). This method, with on-line column solid-phase extraction and electrochemical detection, previously developed for determination of vincristine concentrations in human plasma, was validated for determination of intracellular vincristine concentrations over a range of 1.17 to 50.8 micro g/L with a lower limit of quantitation (LOQ) of 1.17 micro g/L. Linearity of the relationship between concentration and response was characterized by a slope (sd) of 0.0683 (0.0008), an intercept (sd) of 0.0004 micro g/L (0.0085), and a regression coefficient of 0.997 (P = 0.05). Maximum bias and within-day and between-day coefficients of variation (CV) were 14.2%, 4.8%, and 5.7%, respectively. The HPLC detector response did not interfere with the vincristine peaks of five independent MNC sources. The method was used successfully to measure intracellular vincristine concentrations in 8 of 35 bone marrow MNC samples of children newly diagnosed with acute lymphoblastic leukemia (ALL), 3 days after the first injection of 1.5 mg/m2 vincristine. Vincristine concentrations were in the range of 4.0 to 26.4 micro g/L, which was 5 to 20 times the bone marrow plasma concentration. The described HPLC method is accurate and precise and is suitable for detection of intracellular vincristine concentrations in MNC of children with ALL. The results confirm that in vivo vincristine accumulates in bone marrow MNC of patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883226     DOI: 10.1097/00007691-200308000-00004

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  Vincristine attenuates doxorubicin cardiotoxicity.

Authors:  Kanu Chatterjee; Jianqing Zhang; Rong Tao; Norman Honbo; Joel S Karliner
Journal:  Biochem Biophys Res Commun       Date:  2008-06-30       Impact factor: 3.575

2.  Sensitive determination of vincristine in plasma of children with leukaemia using vortex-assisted dispersive liquid-liquid microextraction based on hydrophobic deep eutectic solvent.

Authors:  Mohammad Reza Golpayegani; Reza Akramipour; Simin Gheini; Mazyar Vakili Amini; Farshad Fattahi; Ali Mohebbi; Nazir Fattahi
Journal:  RSC Adv       Date:  2022-01-26       Impact factor: 3.361

3.  High Performance Liquid Chromatographic Assay for the Simultaneous Determination of Posaconazole and Vincristine in Rat Plasma.

Authors:  Hadeel A Khalil; Ahmed F El-Yazbi; Tarek S Belal; Dalia A Hamdy
Journal:  Int J Anal Chem       Date:  2015-12-22       Impact factor: 1.885

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.